{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-000715","form_type":"8-K","ticker":"FENC","cik":"0001211583","company_name":"FENNEC PHARMACEUTICALS INC.","filed_at":"2025-02-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.114391+00:00","generated_at":"2026-05-27T00:50:20.583370+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Fennec's partner Norgine launches PEDMARQSI in Germany for cisplatin-induced hearing loss prevention","bullets":["PEDMARQSI (sodium thiosulfate injection) launched in Germany by Norgine for prevention of ototoxicity in pediatric patients.","First and only approved therapy in EU/UK for cisplatin-induced hearing loss in children 1 month to <18 years with localized solid tumors.","License deal (March 2024) included $43M upfront, up to $230M in milestones, and double-digit tiered royalties (mid-teens to mid-twenties).","Phase 3 data showed ~50% reduction in hearing loss vs. cisplatin alone."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-000715","json":"https://secwatch.observer/filing/0001558370-25-000715.json","markdown":"https://secwatch.observer/filing/0001558370-25-000715.md","text":"https://secwatch.observer/filing/0001558370-25-000715.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1211583/000155837025000715/0001558370-25-000715-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1211583/000155837025000715/fencf-20250207x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T00:50:20.583370+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}